The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
TP53 and breast cancer
Abstract
The TP53 gene (p53) is found altered in breast carcinomas in approximately 20-40% of all cases depending on tumor size and stage of the disease. It seems to be an early event in breast tumorigenesis. Several polymorphisms in the TP53 gene have been detected and their possible roles in breast cancer risk and association to type of cancer developed are discussed. The different mutation spectra seen in geographical and ethnic populations may be used to identify environmental exposure contributing to breast cancer development. The role of TP53 mutation as a prognostic marker is reviewed as well as its role as a predictor for therapy response. All data available on TP53 mutation analyses of human breast carcinomas, as well data from transgenic animal studies and experimental cell studies, support an important role for TP53 in mammary carcinogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao, Z. M., Wu, J., Shen, Z., & Nguyen, M. (2001) · PubMed · Cited by 64
RetractedMolecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Self-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Self-citationCancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Globocan 2000 : cancer incidence, mortality and prevalence worldwide
Ferlay, J., Pisani, P., & Parkin, D. M. (2001) · Medical Entomology and Zoology · Cited by 1,579
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Pollack, J. R., Sørlie, T., Perou, C. M., Rees, C. A., Jeffrey, S. S., Lonning, P. E., Tibshirani, R., Botstein, D., Børresen-Dale, A.-L., & Brown, P. O. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162471999 · Cited by 1,167
Self-citationAas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
A systematic review of genetic polymorphisms and breast cancer risk.
Dunning, A., Healey, C. S., Pharoah, P., Teare, M. D., Ponder, B. A. J., & Easton, D. F. (1999) · PubMed · Cited by 539
Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 460
Geisler, S. B., Lønning, P. E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., & Børresen‐Dale, A. (2001) · PubMed · Cited by 326
Self-citationSomatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
Pharoah, P. D. P., Day, N. E., & Caldas, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690628 · Cited by 308
Kandioler-Eckersberger, D., Ludwig, C., Rudas, M., Kappel, S., Janschek, E., Wenzel, C., Schlagbauer‐Wadl, H., Mittlböck, M., Gnant, M., Steger, G., et al. (2000) · PubMed · Cited by 280
TheTP53 gene, tobacco exposure, and lung cancer
Toyooka, S., Tsuda, T., & Gazdar, A. F. (2003) · Human Mutation · doi:10.1002/humu.10177 · Cited by 276
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271
p53 mutations in breast cancer.
Coles, C., Condie, A., Chetty, U., Steel, C., Evans, H. J., & Prosser, J. (1992) · PubMed · Cited by 241
Langerød, A., Bukholm, I., Bregård, A., Lønning, P. E., Andersen, T. I., Rognum, T. O., Meling, G. I., Lothe, R. A., & Børresen‐Dale, A. (2002) · PubMed · Cited by 204
Self-citationGreenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N., & Foulkes, W. D. (2001) · PubMed · Cited by 196
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns, E., Foekens, J. A., van Vossen, R., et al. (2000) · PubMed · Cited by 196
p53 gene mutation: software and database
Beroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 187
Børresen, A., Andersen, T. I., Eyfjörd, J. E., Cornelis, R. S., Thorlacius, S., Borg, Å., Johansson, U., Theillet, C., Scherneck, S., Hartman, S., et al. (1995) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870140113 · Cited by 178
Prognostic significance of TP53 alterations in breast carcinoma
Andersen, T., Holm, R., Nesland, J., Heimdal, K., Ottestad, L., & Børresen, A. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.383 · Cited by 168
The UMD-p53 database: New mutations and analysis tools
Béroud, C., & Soussi, T. (2003) · Human Mutation · doi:10.1002/humu.10187 · Cited by 157
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 153
The molecular epidemiology of P53 gene mutations in human breast cancer
Hartmann, A., Blaszyk, H., Kovach, J. S., & Sommer, S. S. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(96)10043-3 · Cited by 139
p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis
Sivaraman, L., Conneely, O. M., Medina, D., & O’Malley, B. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221459098 · Cited by 130
Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J. M., Schaid, D. J., & Sommer, S. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1093 · Cited by 127
Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius, S., Børresen‐Dale, A., & Eyfjörd, J. E. (1993) · PubMed · Cited by 119
Self-citationVarley, J. M., Thorncroft, M. R., McGown, G., Appleby, J. E., Kelsey, A. M., Tricker, K. J., Evans, D. G., & Birch, J. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201041 · Cited by 105
Caleffi, M. M., Teague, M. W., Jensen, R. A., Vnencak‐Jones, C. L., Dupont, W. D., & Parl, F. F. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2147::aid-cncr2820730820>3.0.co;2-5 · Cited by 100
Berns, E., van Staveren, I., Look, M., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.187 · Cited by 97
Jain, A. N., Chin, K., Børresen‐Dale, A., Erikstein, B., Lønning, P. E., Kaaresen, R., & Gray, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151241198 · Cited by 93
Self-citationSeshadri, R., Leong, A. S. ‐., McCaul, K. A., Firgaira, F. A., Setlur, V., & Horsfall, D. J. (1996) · International Journal of Cancer · Cited by 90
Jansson, T. E., Inganäs, M., Sjögren, S., Norberg, T., Lindgren, A., Holmberg, L., & Bergh, J. C. S. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2745 · Cited by 86
Overgaard, J. (2000) · Acta Oncologica · doi:10.1080/028418600750013096 · Cited by 85
Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients.
Falette, N., Paperin, M.-P., Treilleux, I., Gratadour, A.-C., Peloux, N., Mignotte, H., Tooke, N., Löfman, E., Inganäs, M., Bremond, A. G., et al. (1998) · PubMed · Cited by 82
Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
Alsner, J., Yilmaz, M. K., Guldberg, P., Hansen, L. L., & Overgaard, J. (2000) · Breast Cancer Research · doi:10.1186/bcr109 · Cited by 79
Racial disparity in the association of p53 gene alterations with breast cancer survival.
Shiao, Y., Chen, V. W., Scheer, W. D., Wu, X., & Corréa, P. (1995) · PubMed · Cited by 76
Powell, B. L., Soong, R., Iacopetta, B. J., Seshadri, R., & Smith, D. R. (2000) · PubMed · Cited by 73
TP53 mutations in familial breast cancer: Functional aspects
Gasco, M., Yuluğ, I. G., & Crook, T. (2003) · Human Mutation · doi:10.1002/humu.10173 · Cited by 71
p53 Missense Mutations in Microdissected High-Grade Ductal Carcinoma In Situ of the Breast
Done, S. J., Eskandarian, S., Bull, S. B., Redston, M. S., & Andrulis, I. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.700 · Cited by 71
TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis
Olivier, M., & Hainaut, P. L. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0390 · Cited by 62
Blaszyk, H., Hartmann, A., Cunningham, J. M., Schaid, D. J., Wold, L. E., Kovach, J. S., & Sommer, S. S. (2000) · International Journal of Cancer · Cited by 53
TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis
Thorlacius, S., Thorgilsson, B., Björnsson, J., Tryggvadóttír, L., Børresen‐Dale, A., Ogmundsdottir, H. M., & Eyfjord, J. E. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00399-4 · Cited by 53
Self-citationIacopetta, B. J., Grieu, F., Powell, B. L., et al. (1998) · PubMed · Cited by 53
Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort.
Norberg, T., Klaar, S., Kärf, G., et al. (2001) · PubMed · Cited by 52
Kučera, E., Speiser, P., Gnant, M., Szabo, L., Samonigg, H., Hausmaninger, H., Mittlböck, M., Fridrik, M., Seifert, M., Kubista, E., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00400-6 · Cited by 37
TP53 mutations in workers exposed to occupational carcinogens: TP53 CARCINOGEN EXPOSURE
Vähäkangas, K. (2003) · Human Mutation · doi:10.1002/humu.10182 · Cited by 37
Done, S. J., Arneson, N. C. R., Özçelik, H., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1006425809069 · Cited by 31
Witte, J. H. D., Foekens, J. A., Lennerstrand, J. A., et al. (1996) · Radboud Repository (Radboud University) · doi:10.1002/(sici)1097-0215(19960422)69:2<125::aid-ijc10>3.0.co;2-8 · Cited by 31
Simão, T. D. A., Ribeiro, F. S., de Amorim, L. M. D. F., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10567 · Cited by 25
Cited by
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,268
Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
Sargent, D. J., Conley, B. A., Allegra, C., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.112 · Cited by 499
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Dai, X., Xiang, L., Li, T., & Bai, Z. (2016) · Journal of Cancer · doi:10.7150/jca.13141 · Cited by 440
Metadata
- Authors
- Børresen-Dale, A.-L.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2003-02-24
- Volume
- 21
- Issue
- 3
- Pages
- 292-300
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W1558526836
- Cited by
- 354
- References
- 53
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.